Ifrah Financial Services Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,298 shares of the biopharmaceutical company’s stock after selling 177 shares during the period. Ifrah Financial Services Inc.’s holdings in Gilead Sciences were worth $292,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of GILD. Hall Laurie J Trustee grew its holdings in Gilead Sciences by 20.0% during the 1st quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 250 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its holdings in Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares during the period. Dubuque Bank & Trust Co. grew its holdings in Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 267 shares during the period. Penserra Capital Management LLC grew its holdings in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares during the period. Finally, Webster Bank N. A. grew its holdings in Gilead Sciences by 51.7% during the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 624 shares during the period. 74.05% of the stock is owned by institutional investors and hedge funds.
In other news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at $3,684,920. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 466,819 shares of company stock valued at $36,740,240. 1.30% of the stock is owned by corporate insiders.
Shares of Gilead Sciences, Inc. (GILD) traded up 0.09% during trading on Friday, reaching $82.36. 12,401,948 shares of the company traded hands. The firm’s 50-day moving average is $77.16 and its 200-day moving average is $70.20. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The stock has a market capitalization of $107.56 billion, a PE ratio of 8.95 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s revenue was down 8.2% on a year-over-year basis. During the same period last year, the company earned $3.08 earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.53%. Gilead Sciences’s dividend payout ratio is presently 22.58%.
ILLEGAL ACTIVITY NOTICE: “Ifrah Financial Services Inc. Has $292,000 Holdings in Gilead Sciences, Inc. (GILD)” was first posted by BBNS and is the property of of BBNS. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://baseballnewssource.com/markets/ifrah-financial-services-inc-has-292000-position-in-gilead-sciences-inc-gild/1566087.html.
GILD has been the subject of a number of analyst reports. William Blair reaffirmed an “outperform” rating on shares of Gilead Sciences in a report on Friday, June 16th. Morgan Stanley reissued an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Robert W. Baird reissued an “outperform” rating and issued a $87.00 price target on shares of Gilead Sciences in a report on Tuesday, August 29th. Berenberg Bank set a $86.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, August 29th. Finally, Royal Bank Of Canada began coverage on shares of Gilead Sciences in a report on Thursday. They issued an “outperform” rating and a $94.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $83.79.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.